Je was op zoek naar: leukæmiceller (Deens - Engels)

administration af clofarabin medfører et hurtigt fald i perifere leukæmiceller.
administration of clofarabine results in a rapid reduction in peripheral leukaemia cells.

dette enzym produceres af leukæmiceller og bevirker, at de formerer sig ukontrolleret.
(44-20) 74 18 84 00 fax (44-20) 74 18 84 16 e-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©emea 2007 reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the emea is acknowledged cells, and causes them to multiply uncontrollably.

i nogle tilfælde oplevede disse patienter en stigning i antallet af cirkulerende leukæmiceller.
in some instances, these patients experienced an increase in the number of circulating leukaemia cells.

ved at blokere bcr-abl-kinase hjælper tasigna med at kontrollere spredningen af leukæmiceller.
by blocking bcr-abl kinase, tasigna helps to control the spread of leukaemia cells.

trisenox blev indgivet intravenøst over 1 til 2 timer, indtil knoglemarven var fri for leukæmiceller, op til maksimalt 60 dage.
trisenox was administered intravenously over 1 to 2 hours until the bone marrow was free of leukaemic cells, up to a maximum of 60 days.

trisenox gives dagligt indtil der er tegn på, at behandlingen virker (knoglemarven er fri for leukæmiceller).
trisenox is given daily until there are signs that the treatment is working (the bone marrow does not contain any leukaemia cells).

dette er tilfældet, når der ingen leukæmiceller er tilbage i knoglemarven, og antallet af blodplader og hvide blodlegemer i blodet er normaliseret.
this is when there are no more leukaemia cells in the bone marrow and the levels of platelets and white blood cells in the blood have recovered.

komplet remission (cr) blev defineret som fravær af synlige leukæmiceller i knoglemarven og perifer restituering af blodplader og hvide blodlegemer.
complete remission (cr) was defined as the absence of visible leukaemic cells in the bone marrow and peripheral recovery of platelets and white blood cells.

som følge af denne biokemiske aktivitet hæmmer nilotinib selektivt proliferationen og inducerer apoptose i cellelinjer og i primære philadelphia-kromosompositive leukæmiceller fra cml-patienter.
as a consequence of this biochemical activity, nilotinib selectively inhibits the proliferation and induces apoptosis in cell lines and in primary philadelphia-chromosome positive leukaemia cells from cml patients.

tasigna er en potent hæmmer af bcr- abl- onkoproteinets abl- tyrosinkinaseaktivitet både i cellelinjerne og i primære philadelphia- kromosompositive leukæmiceller.
tasigna is a potent inhibitor of the abl tyrosine kinase activity of the bcr-abl oncoprotein both in cell lines and in primary philadelphia-chromosome positive leukaemia cells.

administration af clofarabin medførte en dramatisk og hurtig reduktion af perifere leukæmiceller hos 31 ud af de 33 patienter (94 %), som havde et måleligt absolut blasttal ved baseline.
administration of clofarabine resulted in a dramatic and rapid reduction in peripheral leukaemia cells in 31 of the 33 patients (94%) who had a measurable absolute blast count at baseline.

ceplene/il-2 er en immunterapi, som har til formål at inducere immunmedieret destruktion af resterende akut myeloid leukæmiceller og derved forhindre leukæmi-recidiv.
ceplene/il-2 is an immunotherapy which aims to induce immune-mediated destruction of residual myeloid leukaemic cells and thereby to prevent relapse of leukaemia.

stoffet hæmmer selektivt proliferationen og inducerer apoptosis i bcr - abl- positive cellelinier såvel som i friske leukæmiceller fra philadelphia- kromosompositiv (ph+) cml
the compound selectively inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukaemic cells from philadelphia chromosome positive cml and acute lymphoblastic leukaemia (all) patients.

stoffet hæmmer selektivt proliferationen og inducerer apoptosis i bcr- abl-positive cellelinier såvel som i friske leukæmiceller fra philadelphia-kromosompositiv (ph+) cml og hos patienter med akut lymfoblastisk leukæmi (all).
the compound selectively inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh leukaemic cells from philadelphia chromosome positive cml and acute lymphoblastic leukaemia (all) patients.